Related Subjects:
|Malnutrition universal screening tool (MUST)
|Body Mass Index
|Peripherally inserted central catheters (PICC)
|Refeeding syndrome
|Marasmus
Refeeding Syndrome – Updated Feb 2026
The hallmark of refeeding syndrome (RFS) is severe hypophosphataemia (often <0.32 mmol/L), but significant shifts in potassium, magnesium, glucose, thiamine, and fluid balance contribute to life-threatening complications (arrhythmias, respiratory failure, cardiac arrest).
ℹ️ Overview
- RFS occurs when nutrition (carbohydrate-rich, enteral/parenteral/oral) is reintroduced after prolonged starvation/malnutrition, triggering metabolic shifts.
- Can develop in patients with normal pre-refeeding electrolytes due to intracellular depletion during starvation.
- Manifests typically 24–72 hours (up to 5 days) after starting refeeding; preventable with risk identification and cautious approach.
Pathophysiology
- Starvation phase: Low insulin → fat/protein catabolism; intracellular electrolyte depletion masked by normal serum levels.
- Refeeding phase: Carbohydrate → insulin surge → drives glucose uptake + anabolic pathways; massive intracellular shift of phosphate (for ATP/glycolysis), potassium, magnesium → profound hypophosphataemia, hypokalaemia, hypomagnesaemia.
- Other effects: Thiamine depletion (cofactor for glucose metabolism) → Wernicke encephalopathy risk; fluid retention/sodium shifts → oedema, CHF, pulmonary oedema; hyperglycaemia or rebound hypoglycaemia.
Key Metabolic & Clinical Changes
| Abnormality | Consequences | Severity Thresholds (approx.) |
|---|
| Hypophosphataemia | Respiratory/muscle failure, rhabdomyolysis, haemolysis, arrhythmias, seizures | Mild: 0.32–0.5 mmol/L; Severe: <0.32 mmol/L |
| Hypokalaemia | Arrhythmias (VT/VF), weakness, ileus, rhabdomyolysis | <3.0–3.5 mmol/L significant |
| Hypomagnesaemia | Arrhythmias, tetany, seizures, refractory hypokalaemia/hypocalcaemia | <0.5 mmol/L severe |
| Thiamine deficiency | Wernicke–Korsakoff (confusion, ataxia, ophthalmoplegia) | Clinical + low red cell transketolase |
| Fluid overload | Oedema, CHF, pulmonary oedema | Weight gain, raised JVP, crackles |
Risk Stratification (ASPEN 2020 + NICE CG32 influences)
- Moderate Risk (ASPEN: ≥2 criteria): BMI <18.5, weight loss >10% in 3–6 months, minimal intake >5–7 days, low-normal electrolytes, chronic alcohol/chemotherapy.
- Significant/Very High Risk (ASPEN highest; NICE very high): BMI <16 (or <14 extreme), negligible intake >10–15 days, pre-existing low K/PO4/Mg, severe malnutrition (anorexia nervosa, cancer cachexia, chronic alcoholism).
High-Risk Patient Groups
- Anorexia nervosa/eating disorders
- Chronic alcoholism, oncology (chemo/malabsorption)
- Prolonged fasting (>7–10 days), GI losses (vomiting, diarrhoea, fistulae, obstruction)
- Malabsorption (Crohn’s, coeliac), hyperemesis gravidarum
- Post-bariatric surgery, elderly with poor intake, DKA recovery
🩺 Clinical Features
- Early: Fatigue, weakness, paraesthesia, oedema
- Severe: Arrhythmias (AF/VT), cardiogenic shock, respiratory failure (diaphragm weakness), seizures, confusion (Wernicke), rhabdomyolysis, sudden death
- ASPEN diagnostic: ≥10–30% drop in serum P/K/Mg within 5 days of nutrition + organ dysfunction/thiamine-related issues
🔎 Investigations & Monitoring
- Baseline: Weight/BMI/MUST score; U&E, glucose, Ca, PO4, Mg, K, LFTs, thiamine (if suspected), FBC
- Refeeding: Daily electrolytes (PO4, K, Mg) days 1–5 (or twice daily if very high risk/deranged); then alternate days until stable
- Cardiac monitoring (ECG/telemetry) if arrhythmias or very high risk
- Fluid balance, weight daily
💊 Management & Prevention
- Identify risk early - screen all malnourished patients
- Thiamine first: High-dose before any calories - Pabrinex IV (1 pair ampoules TDS for 3–5 days) or oral thiamine 200–300 mg TDS; continue 100–300 mg/day for weeks
- Slow caloric advancement (NICE/ASPEN-aligned):
- High risk: Start 10–20 kcal/kg/day; increase gradually to full needs (25–35 kcal/kg) over 4–7 days
- Very high risk: 5–10 kcal/kg/day initially; monitor closely
- Electrolyte replacement (proactive):
- Phosphate: IV Addiphos (0.3–0.6 mmol/kg/day) or oral Phosphate Sandoz; target >0.5 mmol/L
- Potassium: 2–4 mmol/kg/day (Sando-K/Slow-K oral; IV if severe)
- Magnesium: IV MgSO4 or oral Magnaspartate 0.2–0.4 mmol/kg/day
- Fluid: Careful balance; restrict if overload risk; correct hypovolaemia first
- Multidisciplinary: Dietitian, nutrition team, electrolytes daily; cardiology if cardiac issues
Cases - Refeeding Syndrome Examples
- Case 1 – Anorexia nervosa: 24F, BMI 14, admitted for refeeding. Day 3: confusion, weakness. Labs: PO4 0.3, K 2.7, Mg 0.5. Rx: Slow calories (10 kcal/kg start), IV electrolytes, Pabrinex → recovery.
- Case 2 – Chronic alcoholism: 52M, pancreatitis + starvation. NG feed → arrhythmias/seizures. Severe hypophosphataemia/hypomagnesaemia. Rx: High thiamine, cautious advancement, IV correction.
- Case 3 – Oncology/post-surgical: 68M, oesophageal Ca, 3-week dysphagia → TPN. Oedema, respiratory distress. PO4 0.2, K 2.9. Rx: Immediate electrolytes, fluid monitoring, nutrition support.
Teaching Point 🩺: RFS results from catabolic → anabolic switch with insulin-driven intracellular shifts of PO4, K, Mg.
Prevention key: Screen risk (BMI, intake duration, electrolytes); give thiamine first; start slow (10 kcal/kg high risk, 5 kcal/kg very high); proactive replacement; daily monitoring days 1–5.
Clues: Malnutrition (anorexia, alcohol, cancer, GI losses). Treat early to avoid fatal arrhythmias/respiratory failure.
References (2026 perspective)
- ASPEN Consensus Recommendations for Refeeding Syndrome (2020) – still gold standard.
- NICE CG32: Nutrition Support in Adults (2006/2017) – UK baseline.
- NHS Lanarkshire Refeeding Guideline Update (2025).
- Recent meta-analyses (e.g., Wu et al. 2026 ICU RFS predictors).
